Advaxis, Inc. (ADXS)

Re-Engaging the Immune System to Fight Cancer

Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. The Advaxis technology, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.

Confronting a Global Issue

The World Health Organization estimates that 2.3 million woman are at risk for HPV-associated cervical cancer globally. Developed with cutting edge technology, we are currently investigating ADXS-HPV for the potential to lower that number.
Learn More

Advaxis Platform Technology

Advaxis is pioneering a patented platform technology using bio-engineered bacteria to secrete protein(s) being investigated to redirect the body's immune response to HPV-associated cancer. Much like a Trojan Horse... but on a smaller scale.
Learn More

Clinical Pipeline

Clinical trials for the treatment of HPV-associated cancers

ADXS-HPV, Advaxis’ lead drug candidate is in clinical trials for HPV-associated cancers.

Clinical Pipeline

Visit Advaxis Clinical Pipeline for more information on ADXS-HPV Clinical Program for HPV-associated cancers.

View Clinical Pipeline